<DOC>
	<DOCNO>NCT01071486</DOCNO>
	<brief_summary>Between 100 200 adult undergoing HSCT primary disease include pharmacokinetic/pharmacogenetic study . In preparative protocol Busulfan ( BU ) include indicated know protocol . The GST polymorphism ( A1 , M1 , T1 P1 ) investigate use real time PCR . A correlation pharmacokinetic parameter patient polymorphism perform use know statistical technics comparison . The aim study , correlate demographic data , clinical presentation , clinical outcome include individual , BU kinetics GST polymorphism establish outcome `` map '' receive HSCT primary disease .</brief_summary>
	<brief_title>Busulfan Pharmacokinetic Analysis GST Polymorphism Adults Undergoing Hematological Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Busulfan</mesh_term>
	<criteria>Malignant Benign Diseases need hematological stem cell transplantation part treatment Busulfan part preparative protocol Known sensitivity allergy Busulfan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Busulfan</keyword>
	<keyword>Glutathione S-transferase</keyword>
	<keyword>Genetic polymorphism</keyword>
	<keyword>HVOD</keyword>
	<keyword>GVHD</keyword>
</DOC>